Efficacy of Single-Agent Chemotherapy in Endocrine Therapy-Refractory Metastatic Invasive Lobular Carcinoma.
| Autor: | Mouabbi, Jason A, Qaio, Wei, Shen, Yu, Raghavendra, Akshara Singareeka, Tripathy, Debasish, Layman, Rachel M |
|---|---|
| Předmět: |
THERAPEUTIC use of antimetabolites
THERAPEUTIC use of antineoplastic agents DRUG efficacy CANCER cells CANCER chemotherapy CANCER invasiveness MULTIVARIATE analysis BLACK people METASTASIS RACE TREATMENT effectiveness WHITE people HORMONE receptor positive breast cancer LONGITUDINAL method EVALUATION |
| Zdroj: | Oncologist; Mar2024, Vol. 29 Issue 3, p213-218, 6p |
| Abstrakt: | Background Hormone receptor (HR)-positive, HER2-negative metastatic invasive lobular breast cancer (mILC) is distinct from invasive ductal cancer (IDC) in clinicopathologic and molecular characteristics, impacting its response to systemic therapy. While endocrine therapy (ET) combined with targeted therapies has shown efficacy in ET-sensitive mILC, data on chemotherapy in ET-refractory mILC remain limited. We investigated the efficacy of single-agent capecitabine (CAP) versus taxanes (TAX) in ET-refractory HR+ HER2-negative patients with mILC. Materials and Methods Using data from the MD Anderson prospectively collected breast cancer database, we identified patients with HR+ HER2-negative mILC who received prior ET and first-time chemotherapy in the metastatic setting. We compared outcomes between 173 CAP-treated and 96 TAX-treated patients. Results CAP-treated patients had significantly better median progression-free survival (PFS) than TAX-treated patients (8.8 vs 5.0 months, HR 0.63, P < .001). Overall survival (OS) did not differ significantly between the groups (42.7 vs 36.6 months for CAP vs TAX, respectively, HR 0.84, P = .241). Multivariate analyses for PFS and OS revealed better outcomes in subjects with fewer metastatic sites and those exposed to more lines of ET. Additionally, Black patients showed worse OS outcomes compared to White patients (HR 2.46; P = .001). Conclusion In ET-refractory HR+ HER2-negative mILC, single-agent CAP demonstrated superior PFS compared to TAX. Our findings highlight the potential benefit of CAP in this patient subset, warranting further investigation through prospective trials. [ABSTRACT FROM AUTHOR] |
| Databáze: | Complementary Index |
| Externí odkaz: |
|